Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer

Next Previous
X
Search
Trial Profile

Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use
  • Acronyms pro-duct 001

    • Most Recent Events

    • 28 Jan 2022 Status changed from recruiting to completed.
    • 13 Jul 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2010-020480-21).
    • 17 Apr 2013 Status changed from planning to recruiting as reported by German Clinical Trials Register.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top